John Scagnelli, MD
Neurology · Raleigh, NCNPI 1437268265
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $293,276 of the $429,415 with a category attached, or 68.3%. It is spread thinly across 57 manufacturers, the largest accounting for just 20.9%. Reporting peaked in 2019 at $118,430 and has fallen 52.4% since, to $56,365 in 2025. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,867 payments — averaging $230.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$90K
- Sanofi$80K
- Genentech USA, Inc.$64K
- TG Therapeutics, Inc.$63K
- AstraZeneca$33K
- Amgen$31K
- plus $69K from 51 others
Across 427 payments — averaging $20,866 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5M
- Sanofi$1.8M
- Genentech, Inc.$814K
- Biogen$473K
- TG Therapeutics, Inc.$384K
- Janssen Research & Development, LLC$206K
- plus $272K from 7 others
What the payments were for
- Consulting fees$82,07619%
- Speaking & faculty fees$293,27668%
- Travel & lodging$22,9155%
- Food & beverage$30,4747%
- Education$6740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$429,415 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 51 | $2,066,859 |
| Kesimpta PenOfatumumab | 101 | $1,132,994 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $657,689 |
| TysabriNatalizumab | 65 | $552,100 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 30 | $323,828 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $302,896 |
| MayzentSiponimod | 26 | $246,422 |
| GilenyaFingolimod Hcl | 15 | $225,808 |
| Tascenso OdtFingolimod Lauryl Sulfate | 14 | $190,657 |
| RebifInterferon Beta-1a/Albumin | 11 | $134,518 |
| AmpyraDalfampridine | 19 | $126,453 |
| UbrelvyUbrogepant | 52 | $82,344 |
| NuplazidPimavanserin Tartrate | 16 | $71,423 |
| Dalfampridine ErDalfampridine | 139 | $57,185 |
| Emgality PenGalcanezumab-Gnlm | 49 | $49,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $2,239 | $2,066,85951 claims |
| Grifols USA, LLCGamunex-C | $162 | $657,68928 claims |
| BiogenTysabri | $89,622 | $552,10065 claims |
| NovartisMayzent, Gilenya | $21,108 | $472,23041 claims |
| CSL BehringPrivigen | $589 | $302,89620 claims |
| Cycle Pharmaceuticals IncTascenso Odt | $3,174 | $190,65714 claims |
| EMD Serono, Inc.Rebif | $27,811 | $134,51811 claims |
| Acorda Therapeutics, IncAmpyra | $164 | $126,45319 claims |
| AbbVieUbrelvy, Qulipta | $1,541 | $120,80388 claims |
| Acadia Pharmaceuticals IncNuplazid | $83 | $71,42316 claims |
| PfizerNurtec Odt | $407 | $22,46123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $125 | $5,17611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.
Other neurology in Raleigh
- Timothy RyanRaleigh$85K
- Casey JeffreysRaleigh$82K
- Sommer PhilipsRaleigh$46K
- Steven FreedmanRaleigh$42K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
- Kevin KahnDurham$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.